Exicure Reaches Preliminary Settlement in Derivative Lawsuits
TipRanks (Thu, 2-Apr 5:55 PM ET)
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Globe Newswire (Thu, 2-Apr 4:01 PM ET)
Exicure, Inc. Reports Full Year 2025 Financial Results
Globe Newswire (Wed, 25-Mar 4:18 PM ET)
Globe Newswire (Thu, 5-Feb 7:00 AM ET)
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
Globe Newswire (Wed, 21-Jan 7:00 AM ET)
Market Chameleon (Tue, 9-Dec 4:52 AM ET)
Market Chameleon (Tue, 9-Dec 2:05 AM ET)
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
Exicure trades on the NASDAQ stock market under the symbol XCUR.
As of April 6, 2026, XCUR stock price was flat at $4.19 with 2,156 million shares trading.
XCUR has a beta of -0.06, meaning it tends to be less sensitive to market movements. XCUR has a correlation of 0.00 to the broad based SPY ETF.
XCUR has a market cap of $26.71 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, XCUR traded as high as $36.00 and as low as $1.44.
The top ETF exchange traded funds that XCUR belongs to (by Net Assets): VXF, IWC, VTI.
XCUR has underperformed the market in the last year with a price return of -65.9% while the SPY ETF gained +17.9%. XCUR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.9% and -11.8%, respectively, while the SPY returned -3.4% and +0.3%, respectively.
XCUR support price is $3.91 and resistance is $4.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XCUR shares will trade within this expected range on the day.